EUVIMEDEUVIMED entdecken
Crossref

A PD-L1 tropism-expanded oncolytic adenovirus enhanced gene delivery efficiency and anti-tumor effects

Shengsheng Mei, Shanshan Peng, Eu Gene Vong, Jinbiao Zhan

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112393 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Shengsheng Mei und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Cancer Institute of the Second Affiliated Hospital (Key Laboratory of Cancer Prevention and Intervention, China National …. Hauptthemen laut MEDLINE: B7-H1 Antigen, Oncolytic Virotherapy, Oncolytic Viruses, Adenoviridae. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Foundation for Innovative Research Groups of the National Natural Science Foundation of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recombinant adenovirus serotype 5 (Ad5)-mediated virotherapy is a maturing technique in cancer treatment. However, the utility of adenovirus (Ad) has been limited by low expression of coxsackievirus and adenovirus receptor (CAR) in cancer cells resulting in poor infectivity of Ads. To overcome the problem, we aimed to develop a novel tropism-modified oncolytic adenovirus, ZD55-F-HI-sPD-1-EGFP, which contains the epitope of PD-1 (70-77aa) at the HI-loop of Ad fiber. Trimerization of Fiber-sPD-1 was confirmed by immunoblot analysis. ZD55-F-HI-sPD-1-EGFP shows a remarkable improvement in viral infection rate and gene transduction efficiency in the PD-L1-positive cancer cells. Competition assays with a PD-L1 protein reveals that cell internalization of ZD55-F-HI-sPD-1-EGFP is mediated by both CAR and PD-L1 at a high dose. The progeny virus production capacity showed that sPD-1 incorporated fiber-modified oncolytic Ad replication was not affected. Furthermore, treating with ZD55-F-HI-sPD-1-EGFP significantly increased viral infection rate and enhanced anti-tumor effect in vivo. This study demonstrates that the strategy to expand tropism of oncolytic Ad may significantly improve therapeutic profile for cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenOncolytic VirotherapyOncolytic VirusesAdenoviridaeViral TropismHumansAnimalsCell Line, TumorMiceNeoplasmsXenograft Model Antitumor AssaysMice, Inbred BALB CFemaleCoxsackie and Adenovirus Receptor-Like Membrane ProteinGene Transfer TechniquesGenetic TherapyGenetic VectorsHEK293 Cells

Stichwörter der Autor:innen

Oncolytic adenovirusPD-L1 tropism-expandedViral infectivitysPD-1

Substanzen

B7-H1 AntigenCD274 protein, humanCoxsackie and Adenovirus Receptor-Like Membrane Protein

Autor:innen und Institutionen

  • Department of Biochemistry, Cancer Institute of the Second Affiliated Hospital (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), School of Medicine, Zhejiang University, Hangz…

Förderung

  • Foundation for Innovative Research Groups of the National Natural Science Foundation of China
  • National Natural Science Foundation of China

Zitieren

APA

Mei, S., Peng, S., Vong, E. G., & Zhan, J. (2024). A PD-L1 tropism-expanded oncolytic adenovirus enhanced gene delivery efficiency and anti-tumor effects. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112393

Vancouver

Mei S, Peng S, Vong EG, Zhan J. A PD-L1 tropism-expanded oncolytic adenovirus enhanced gene delivery efficiency and anti-tumor effects. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112393

BibTeX
@article{Mei2024,
  author = {Mei, Shengsheng and Peng, Shanshan and Vong, Eu Gene and Zhan, Jinbiao},
  title = {A PD-L1 tropism-expanded oncolytic adenovirus enhanced gene delivery efficiency and anti-tumor effects},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112393}
}
Kostenlos starten →